Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...

European Research Program with Eleven Institutions from Six Countries In 2023, Merck KGaA, Darmstadt, Germany and Intel announced the joint investment in the academic research program for a period ...

Winner to be Presented at BIO-Europe 2024 in Stockholm, SwedenROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ ...

DARMSTADT, Germany — Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Intel Corporation, one of the world’s largest semiconductor designers and manufacturers, have begun ...

Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on November 1 and set a price target ...